# Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

> **NCT04276493** · PHASE1,PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 71 (actual)

## Conditions studied

- Breast Cancer
- Gastric Cancer
- Gastroesophageal Junction Cancer

## Interventions

- **BIOLOGICAL:** Zanidatamab
- **DRUG:** Docetaxel
- **BIOLOGICAL:** Tislelizumab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT04276493
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-26
- **Primary completion:** 2023-12-07
- **Final completion:** 2024-10-31
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2024-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04276493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04276493, "Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04276493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*